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a b s t r a c t
The nucleoprotein (NP) of inﬂuenza A virus plays a critical role in the formation of viral ribonucleopro-
tein (vRNP) complex. However, it remains unclear which key residues in NP are associated with the
assembly of vRNP and contribute to virus replication. Here, a highly conserved aspartic acid at residue 88
(D88) of NP was identiﬁed by molecular docking of NP with the Fv region of a broad-spectrum anti-NP
mAb 19C10 and further demonstrated to be an important residue contributes to the RNP activity,
virus growth in MDCK cells and replication in lungs of infected mice by comparing recombinant
wild-type A/WSN/1933 virus to the mutant virus that contains an alanine instead of aspartic acid at NP
residue 88. D88 was also predicted to interact with PB2 by molecular docking and further veriﬁed
by immunoprecipitation. These ﬁndings provide new information for understanding the interaction
between NP and other polymerase subunits in virus replication.
& 2014 Elsevier Inc. All rights reserved.
1. Introduction
Inﬂuenza virus has three distinct serotypes (A, B, and C) on the
basis of the antigenic properties of the internal nucleoprotein (NP)
and matrix proteins (M1) (Lamb and Krug, 2001). Inﬂuenza A virus
is the most clinically important serotype because it is endemic in
animals and causes annual epidemics in humans. Seasonal
epidemics of human H1N1 and H3N2 have been associated with
an estimated three to ﬁve million cases of severe illness and about
250,000 to 500,000 deaths worldwide every year (World Health
Organization, 2009). Periodic and high-mortality pandemics have
posed greater threats to global human health as well as economic
or social stability (Medina and Garcia-Sastre, 2011; Webster et al.,
1992). Emerging avian inﬂuenza A viruses such as H5N1, H7N9
cause sporadic human death due to close contacts with infected
poultry (Ai et al., 2013; Gao et al., 2013; Kandun et al., 2008).
Inﬂuenza A virus contains eight segmented, single-stranded,
negative-sense RNA genome. The nucleoprotein (NP), encoded by
inﬂuenza A virus segment 5, is highly expressed during virus
replication and found to be abundant in the viral particle. The NP
protein has been used in two important practical applications. It is
a useful diagnostic target due to its high degree of sequence
conservation and has been used to distinguish between inﬂuenza
A and B virus infections in a routine clinical setting. Furthermore,
NP is a promising drug target because it is a major component of
the vRNP complex, consisting of RNA, NP and the RNA-dependent
RNA polymerases (PA, PB1, and PB2) (Kao et al., 2010; Klumpp
et al., 1997; Noda et al., 2012; Zheng and Tao, 2013). The vRNP
complex is responsible for viral RNA replication and transcription
in the virus life cycle (Moeller et al., 2012; Noda et al., 2006;
Portela and Digard, 2002). The assembly integrity of the vRNP will
affect its activity and change the efﬁcacy of the virus replication,
virus virulence and virus spreading. Hence, it is important to
understand how the vRNP is assembled and how the vRNP control
the virus replication.
It has been reported that NP displays RNA-binding, polymerase
binding and NP-NP homo-oligomerization properties in the vRNP
complex. Further identiﬁcation of the critical amino acids of NP
relevant to the interaction with other subunits within the vRNP
complex will be helpful to understand the role of NP in the viral
replication. Several NP interaction sites have been identiﬁed, such
as two RNA binding domains (residues 1 to 77 and 79 to 180), two
PB2 binding domains (residues 1 to 166 and 255 to 498) and three
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viral polymerase binding amino acids (R204, W207 and R208)
(Biswas et al., 1998; Marklund et al., 2012). However, more work is
needed to ﬁnd out more such critical amino acids in NP. In our
previous study, we reported the selection of an NP speciﬁc
monoclonal antibody (mAb) designated as 19C10 that had cross-
reactivity with all inﬂuenza A viruses in a Dot-ELISA assay (Chen et
al., 2008; Chen et al., 2010). We speculated that the conserved
epitope recognized by mAb 19C10 may be associated with the
assembling integrity of vRNP and play an important role in virus
replication. To test this hypothesis, we used molecular docking
methods to construct the interaction between NP and Fv region of
mAb 19C10 and identiﬁed a highly conserved amino acid at
residue 88 (D88) which is responsible for the binding of mAb
19C10 in the NP. We further investigated the role of D88 in
inﬂuenza A virus replication by characterizing a D88 mutant virus
(rWSN-D88A) in vitro and in vivo. The results showed that D88 in
NP is related directly to the replication of inﬂuenza A virus and
acts as a critical amino acid for the binding of NP with PB2.
These ﬁndings provide new clues for understanding inﬂuenza A
virus replication and a potential target for the development of
antiviral drugs.
2. Results
2.1. Broad cross-reactivity of mAb 19C10 with inﬂuenza
A virus strains
A panel of anti-NP of inﬂuenza A virus mAbs was generated and
divided into three classes (I, II, III) based on their reactivity to
different inﬂuenza A viruses in our previous study(Gui et al., 2014).
One representative mAb 19C10 of class II has been used as the
capture antibody to develop a highly sensitive rapid inﬂuenza
A virus detection assay in a Dot-ELISA system (Chen et al., 2010).
In this study, three classes of NP mAb were coated respectively
as capture antibody and compared for their abilities to detect
different inﬂuenza A viruses. Table 1 shows that the assay used
19C10 of class II NP mAb as capture antibody can detect all sixteen
inﬂuenza A virus strains belonging to eleven different subtypes at
an HA titer as low as 0.01. These viruses included H1, H2, H3, H4,
H5, H6, H7, H8, H9, H12 and H13 subtype virus strains. But assays
used the other two classes of NP mAb as capture antibody failed to
detect some of the sixteen inﬂuena A viruses. All these assays did
not detect two inﬂuenza B virus strains as negative controls even
at an HA titer of 10. These results suggested that the mAb 19C10
should recognize a highly conserved epitope in NP of different
subtypes of inﬂuenza A virus.
2.2. Characterization of mAb 19C10
To know the activity of the mAb 19C10 in natural or denatured
conditions, it was characterized in indirect ELISA, Western blot and
indirect immunoﬂuorescence assay (IFA), showing that mAb 19C10
(IgG2a) had good reactivity with inﬂuenza A H1N1 virus strain
A/WSN/1933 (WSN) in these three assays, but had no cross-reactivity
with inﬂuenza B virus strain B/Wisconsin/01/2010 (B/Wis/01) as a
negative control (Fig. 1A–C). Considering that 19C10 can react
with NP antigen in Western blot, it is speculated that 19C10 might
recognize a linear epitope on NP. To determine this, three
overlapping fragments of recombinant NP derived from WSN,
designated Fragment 1 (1-120aa), Fragment 2 (110-301aa) and
Fragment 3 (293-498aa) were expressed in E.coli by fusing his-tag
and their expressions were conﬁrmed with anti-his-tag polyclonal
antibody (Proteintech) in Western blot (Fig. 1D). Interestingly,
Western blot results showed that mAb 19C10 reacted with none of
the three fragments of recombinant NP (rNP) though it can react
with rNP with full-length NP. Taken together, mAb 19C10 should
recognize a native conformational epitope on NP of inﬂuenza A virus
(Fig. 1D).
2.3. Prediction of the 19C10 epitope based on the three-dimension
complex structure of NP with 19C10
To probe the mechanism of speciﬁc binding and investigate the
key amino acid residues as binding epitopes, the three-dimension
structure of mAb 19C10 in complex with NP was constructed using
molecular docking and optimized by molecular dynamics simula-
tion. First, the Fv region sequences of light chain and heavy chain
of mAb 19C10 were sequenced and their CDR sequences were
indicated (Fig. 2A). After the Fv region of 19C10 was sequenced,
the homology modeling was processed. Molecular docking of
19C10 Fv region with NP crystal structure (PDB accession number:
2Q06) was performed with ZDOCK and RDOCK softwares.
Table 1
Comparison of three classes of NP mAb as capture antibody for the detection of 16
different subtypes of inﬂuenza A virus and 2 inﬂuenza B viruses in a Dot-
ELISA assay.
Virus type Virus strains Virus
titer
(HA
titer)
Capture mAb in
Dot-ELISAa
15H2
(Ib)
19C10
(II)
1F2
(III)
Inﬂuenza A
virus
A/New Caledonia/20/1999
(H1N1)
0.01 þ þ 
A/Brisbane/59/2007 (H1N1) 0.01 þ þ 
A/California/04/2009
(H1N1pdm09)
0.01  þ 
A/Wild duck/Shantou/992/
2000 (H2N8)
0.01 þ þ þ
A/Moscow/10/1999 (H3N2) 0.01 þ þ 
A/Brisbane/10/2007 (H3N2) 0.01 þ þ 
A/Duck/Siberia/378/2001
(H4N6)
0.01  þ þ
A/Chicken/HK/YU22/2002
(H5N1)
0.01 þ þ þ
A/Vietnam/1194/2004 (H5N1) 0.01 þ þ þ
A/Teal/Hong Kong/W312/1997
(H6N1)
0.01  þ þ
A/Duck/Jiangxi/1786/2003
(H7N7)
0.01 þ þ þ
A/Turkey/Ontario/6118/1968
(H8N4)
0.01 þ þ þ
A/Duck/Hong Kong/G9/1997
(H9N2)
0.01 þ þ þ
A/Duck/Hong Kong/Y280/1997
(H9N2)
0.01 þ þ þ
A/Duck/Vietnam/G18/2009
(H12N5)
0.01 þ þ þ
A/Gull/Maryland/704/1977
(H13N6)
0.01  þ þ
Inﬂuenza B
virus
B/Florida/4/2006 10   
B/Malaysia/2506/2004 10   
þ , positive;  , negative.
a Dot-ELISA is a ﬂow-through sandwich immunoassay that uses two antibodies.
In this study, the anti-NP mAbs, immobilized on a nitrocellulose membrane, serves
as the capture antibodies, and the other, polyclonal antibody, labeled with horse-
radish peroxidase was used as the detecting antibody. The procedure involves
mixing 200 ml of viruses with 400 ml of lysis buffer. This mixture was ﬁltered in a
microtiter-like well that had a permeable membrane located at the bottom of the
well with the antigen captured during the ﬁltration process. The entire test
procedure can be completed in 30 min and the results can be read visually. In
Dot-ELISA, anti-NP mAbs were coated at 5 mg/dot. Virus stocks used in Dot-ELISA
test were diluted from 10 HA titer to 0.01 HA titer.
b Three classes of NP speciﬁc mAb (Classes I, II, and III) were characterized
previously (Gui et al., 2014) and were coated respectively here to compare their
detection of inﬂuenza A viruses.
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The pose with the highest scores both in ZDOCK and RDOCK was
selected for 19C10 epitope mutation analysis. In the stable com-
plex conformation, the structure of 19C10 Fv fragment was
modeled with a homology method, and the structure of NP was
derived from its x-ray crystal structure (Fig. 2B and C). The results
showed that ten putative amino acids F71, R74, R77, D88, D89, K90,
K91, E114, Q122 and E127 might be relevant to the binding site of
mAb 19C10, which showed in red in complex structure of NP and
19C10 (Fig. 2D) and be labeled in the enlarged picture (Fig. 2E).
2.4. Mutational analysis of the epitope recognized by mAb 19C10
After the alignment of NP gene sequences from 18,000 different
subtype inﬂuenza A virus strains in GenBank, we found that ﬁve of
the ten putative amino acids were highly conserved in inﬂuenza A
viruses (Fig. 3A). To further investigate whether these ﬁve con-
served amino acids are the key residue recognized by mAb 19C10,
alanine substitution mutants were constructed for each of the ﬁve
conserved amino acids. The mutant recombinant NP proteins were
then analyzed by Western blot and ELISA (Fig. 3B and D). The
result of Western blot and ELISA revealed that D88 in NP of
inﬂuenza A virus is the key amino acid recognized by mAb 19C10,
for the binding of mAb 19C10 to the mutant rNP was abolished in
Western blot and weakened in ELISA due to the substitution of
aspartic acid to alanine at residue 88 in NP. Considering that the
conformation of native protein can be preserved better in ELISA
than in Western blot, the difference of the binding activity
between Western blot and ELISA implied that the binding of
19C10 with NP may be associated with conformation change of
NP protein. Such effect on antibody binding activity of NP in
Western blot is more signiﬁcant than in ELISA. After identiﬁcation
of the key residue of the 19C10 epitope on NP, we mapped it in
three-dimension model based on the x-ray crystal structure
of NP (PDB accession number: 2Q06). The image showed that
D88 is located in the surface of the body domain of NP in three-
dimension structure (Fig. 3C), showing this epitope is readily
accessible under native conditions. As the body domain helices
1 to 4 (residues 1–148) of NP are associated with RNA binding and
PB2 binding (Mena et al., 1999), D88 may also have the necessity
for preservation of the function of NP.
2.5. Contribution of amino acid D88 in NP to the activity of RNP
As mentioned above, NP is of great importance in high-activity
RNP assembling, virus genome transcription and replication of
inﬂuenza A virus. To identify whether D88 in NP of inﬂuenza A
virus contributes to the formation of the RNP, we examined the
effect of D88 in virus RNP activity in 293T cells. The RNP genes,
PB1, PB2, PA including a wild-type NP gene (NP-WT) or an alanine
substitution mutant NP gene (NP-D88A) derived from three
inﬂuenza A H1N1 viruses, A/WSN/1933 (WSN), A/PR/8/1934 (PR8)
and A/California/04/2009 (CA4), along with a reporter plasmid
containing noncoding sequences from the inﬂuenza virus M seg-
ment and a luciferase gene driven by the human RNA polymerase I
Fig. 1. Characterization of the broad-spectrum anti-NP of inﬂuenza A virus mAb 19C10. (A) Indirect ELISA of mAb 19C10 with E.coli-expressed recombinant NP from
inﬂuenza A virus CA/4/09 (H1N1pdm09). One anti-NP of inﬂuenza B virus mAb 10B6 as a negative control. The optical density at a wavelength of 450 nm was measured. (B)
Western blots of mAb 19C10 with inﬂuenza A H1N1 virus strain A/WSN/1933 (WSN). One inﬂuenza B virus strain B/Wisconsin/01/2010 (B/Wis/01) as a negative control.
Samples were loaded with virus lysates. 1.0 mg/ml of mAb 19C10 was used at a dilution of 1:1000, anti-mouse HRP conjugated IgG was used as a secondary antibody at a
dilution of 1:1000. (C) Indirect immunoﬂuorescence assay of mAb 19C10 with WSN and B/Wis/01 infected MDCK cells. Cells were ﬁxed at 24 h post infection and stained
with anti-NP (green) mAb 19C10 and DAPI (blue). (D) Western blots of mAb 19C10 and anti-his-tag polyclonal antibody with E.coli-expressed NPs from different length of NP
gene of inﬂuenza A virus CA/4. Full-length (1-498aa), Fragment 1 (1-120aa), Fragment 2 (110-301aa) and Fragment 3 (293-498aa).
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promoter were cotransfected into 293T cells, respectively. The RNP
activities were found to be signiﬁcantly higher in all three wild-type
NP gene transfected cells than that in mutant ones, showing that
D88 plays an important role in maintaining RNP activity (Fig. 4A).
2.6. Replication kinetics of recombinant virus with wild-type or
mutant NP gene in cells and mice
To determine whether the amino acid D88 in NP of WSN has
any effect on virus replication, we generated a recombinant wild-
type WSN virus (rWSN-WT), along with a mutant virus containing
an alanine at NP residue 88 instead of aspartic acid (rWSN-D88A),
using reverse genetics. The recombinant wild-type and mutant
virus could be rescued from transfected 293T cells and subse-
quently ampliﬁed in MDCK cells. To further determine the repli-
cative abilities of recombinant WSN virus, we tested virus titers at
different time points after infection in MDCK cells. The result
revealed that the growth rate of rWSN-WT was signiﬁcantly
higher than that of rWSN-D88A at 12, 24 and 36 h post infection
in MDCK cells (Fig. 4B).
To further compare the replicative abilities of the wild-type and
mutant WSN virus in vivo, we challenged BALB/c mice with each
virus intranasally to evaluate the virus titers in lung tissues. The
lung tissues of three mice in each group at 12, 24 and 36 h post
infection were homogenized and detected for TCID50 titer. The
virus titers in the lungs increased less sharply in mice infected
with the D88A mutant virus compared to the wild type virus
(Fig. 4C), implying that the aspartic acid at residue 88 in NP may
contribute to virus replication in mice.
2.7. Contribution of amino acid D88 in NP to the virus genome
replication of inﬂuenza A virus
To further understand the mechanism how D88 contributes to
virus replication, we examined the replication of NP and NS1
genes (vRNA) in rWSN-WT and rWSN-D88A infected cells at
Fig. 2. Molecular docking of the Fv region of mAb 19C10 with NP. (A) The CDR sequences of mAb 19C10. (B) The three-dimensional structure of mAb 19C10 Fv region derived
from computer-guided modeling method. The Heavy chain and light chain are indicated in olive green and dark blue, respectively. (C) Surface presentation of mAb 19C10 Fv
region. The CDR loops are indicated in different colors. (D) The three-dimensional complex structure of mAb 19C10 Fv region with x-ray crystal structure of monomer NP
from H5N1. Amino acids contacted with mAb 19C10 Fv region in NP monomer are showed in red. (E) Location of ten putative amino acids (F71, R74, R77, D88, P89, K90, K91,
E114, Q122 and E127) of NP of inﬂuenza A viruses as 19C10 epitope by molecular docking. The amino acid numbers are indicated in one monomer of NP.
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indicated time points with RT-PCR. The vRNA levels of rWSN-WT
were signiﬁcantly higher than rWSN-D88A at 8 h post infection
(Fig. 4D), conﬁrming that mutation of D88 residue is able to
decrease the replication of virus genomes of inﬂuenza A virus.
2.8. Contribution of amino acid D88 to interaction between
NP and PB2
Previous studies have demonstrated that the region (aa 1-160) of
NP is involved in the binding of PB2 (Biswas et al., 1998; Mena et al.,
1999). Considering that the amino acid D88 contributes to the viral
replication and just locates in this binding region of NP with PB2, it is
imperative to further explore whether this D88 residue is located at
the binding interface between NP and PB2. Hence, we carried out a
docking of the atomic structure of the NP monomer into the cryo-EM
structure to predict the interaction interface (Coloma et al., 2009).
Interestingly, the docking result showed that D88 in NP was
expectedly at the binding interface between NP and PB2 which the
contact region was enlarged on the right (Fig. 5A). To conﬁrm
whether the D88 residue contributes to a direct physical interaction
between NP and PB2, we performed co-immunoprecipitation experi-
ments with 293T cells transiently cotransfected with plasmids
encoding wild-type NP (NP-WT) or mutant NP of WSN (NP-D88A,
the substitution of aspartic acid to alanine at residue 88 in NP) along
with PB2 gene or PB1 gene from WSN. Expression of the recombi-
nant NP and PB2 was detected with anti-NP and anti-PB2 murine
antibodies, respectively (Fig. 5B lower panel). Cell lysates were then
immunoprecipitated with anti-NP rabbit polyclonal antibody and
subsequently immunoblotted with anti-PB2 murine antibody. As
shown in the upper panel of Fig. 5B, co-immunoprecipitation of
PB2 with NP showed that the band intensity of PB2 with NP-D88A
was weaker than that with NP-WT. The relative intensities of the
bands in Western blot were further quantiﬁed using Quantity One
V4.62 software (Bio-Rad), showing the PB2 binding of NP-D88A is
signiﬁcantly reduced than that of NP-WT (po0.01) (Fig. 5C). Simi-
larly, co-immunoprecipitation of PB1 with NP-WT or NP-D88A was
determined in the same system using anti-NP rabbit antibody and
anti-PB1 murine antibody. The results showed that the PB1 bands in
Western blot had the almost same intensity both for NP-WT and NP-
D88A (Fig. 5D and E), showing that D88 in NP might not affect the
binding of PB1. Taken together, these results demonstrate that the
residue D88 should play a critical role in the physical interaction
between NP and PB2 but not PB1. To further conﬁrm the effect of D88
at the interaction of NP with PB2 in the context of the RNP complex,
wild-type and mutant NP of WSN were coexpressed together with
three polymerase genes (PA, PB1, and PB2). Immunoprecipitates were
then analyzed by Western blot, using anti-NP, anti-PA, anti-PB1 and
anti-PB2 murine antibodies to conﬁrm the effect of D88 on copre-
cipitation of NP with PB2. Co- immunoprecipitation results showed
that the band intensities of all three polymerase PA, PB1, and PB2
with NP-D88A were signiﬁcantly weaker than that with NP-WT
(Fig. 5F and G), conﬁrming that the residue D88 directly affect the
physical binding of NP with PB2 and might further affect the activity
of the vRNP complex by diminishing the binding of PB2 with other
subunits in the complex. These results provide evidence supporting
the role of D88 in the interaction between NP and PB2, demonstrat-
ing that the residue D88 is a key amino acid for maintenance of the
vRNP activity.
3. Discussion
NP is an essential protein in the life cycle of inﬂuenza virus. Till
date, we have known that a ring structure is formed by three NP
oligomers in the absence of RNA based on three available NP
structures of inﬂuenza virus, they all assume the overall shape of a
crescent with a head and a body domain (Ng et al., 2012; Ng et al.,
2008; Ye et al., 2006). Such complicated conformation makes it
extremely difﬁcult to characterize the epitopes in NP, especially for
conformational epitopes. Till date, only several amino acids have
been identiﬁed as potential conformational antigenic sites in NP
based on sequence analysis and antigenic analysis with anti-NP
mAbs (Varich and Kaverin, 2004; Varich et al., 2009). In this paper,
we have identiﬁed aspartic acid at residue 88 as a key amino acid
Fig. 3. Identiﬁcation of the key amino acid of the epitope recognized by mAb 19C10. (A) Multiple sequence alignment of NP in the indicated amino acid positions. A total of
18,000 NP sequences from GenBank were aligned using Clustal W. (B) Coomassie Staining SDS-PAGE and Western blots of E.coli-expressed wild-type NP (rNP-WT) and
alanine substitution mutant rNPs with mAb 19C10. The mAb 19C10 was used as the primary antibody at a dilution of 1:1000, anti-mouse HRP conjugated IgG was used as a
secondary antibody at a dilution of 1:1000. The stock mAb 19C10 solution with a concentration of 1.0 mg/ml. (C) Location of the key residue D88 (red) recognized by mAb
19C10 in trimer NP structure of inﬂuenza A H5N1 virus. The regionwas enlarged in the picture on the right. (D) ELISA of mAb 19C10 with E.coli-expressed wild-type NP (rNP-
WT) and alanine substitution mutant NP (rNP-D88A).
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of a highly conserved conformational B-cell epitope in NP of
inﬂuenza A virus by using molecular docking and site-speciﬁc
mutagenesis methods, suggesting that combination of molecular
docking and mutational analysis could be used as a promising
analytic way to identify and characterize this conformational epitope.
NP plays a critical role in virus replication and transcription of
inﬂuenza virus. It is documented that NP protein interacts with
PB1, PB2 and virus RNA to form the vRNP which is responsible for
the virus replication (Portela and Digard, 2002). The assembly of
the vRNP complex is important to maintain high level of virus
replication (Jorba et al., 2009). Identiﬁcation of the amino acids
responsible for the interaction between NP and other polymerase
subunits can provide useful information to understand details of
vRNP assembly and the impact of these residues on virus replica-
tion. The crystal structure of oligomeric NP showed that the
C-terminal tail of NP mediates interactions between NP molecules,
while the N-terminal portion and central parts bind to viral RNA
(Ng et al., 2008; Ye et al., 2006). In this study, we found the 88
amino acid, aspartic acid (D), in the N-terminal of NP are
important for virus replication both in vitro and in vivo and also
found that this aspartic acid at residue 88 replaced by alanine
decreased the binding activity of NP with PB2, indicating that this
Fig. 4. Residue D88 in NP contributes to inﬂuenza A virus replication. (A) D88 in NP contributes to the RNP activity of inﬂuenza A virus. Polymerase complex components
derived from three inﬂuenza A H1N1 viruses, A/WSN/1933 (WSN), A/PR/8/1934 (PR8) and A/California/04/2009 (CA4) together with their wild-type NP genes (NP-WT) or
mutant NP genes (NP-D88A, containing an alanine at NP residue 88 instead of aspartic acid) were cotransfected alongside a reporter plasmid that contains noncoding
sequence from the M segment of inﬂuenza A virus and the luciferase gene driven by the Poll promoter into 293T cells. The luciferase activity in triplicate cultures was
estimated at 24 h post transfection. Error bars represent the standard deviation of triplicate assays for each time point. Western blot of anti-NP mAb 4D2 with the NPs in
different expressions was used to prove similar expression level of different NP mutants. The 4D2 is a broadly reactive mAb recognizing a linear B-cell epitope in NP of
inﬂuenza A virus (Gui et al., 2014). (B) in vitro growth kinetics of rWSN-WT and rWSN-D88A strains. MDCK cells were infected with 500 TCID50 of rWSN-WT and rWSN-D88A
strains containing an alanine at NP residue 88 instead of aspartic acid, respectively. At the indicated time points post infection, the virus titers in the cell culture supernatants
were measured. Error bars represent the standard deviation for each time point. (C) Replication of rWSN-WT and rWSN-D88A strains in mice lung tissues. Mice were
infected with 25 ml of 106 TCID50/ml rWSN-WT and rWSN-D88A strains. After infection, three mice from each group were euthanized and lung tissues were collected at the
indicated time points. Virus titers of the supernatants of homogenized lung tissues were measured. Error bars represent the standard deviation for each time point. (D) D88
in NP relates to virus genome replication. MDCK cells were infected with 10000 TCID50 rWSN-WT and rWSN-D88A strains, respectively. NP and NS1 vRNA levels in infected
cells were estimated by RT-PCR at indicated time points.
Fig. 5. Residue D88 in NP contributes to the binding of NP with PB2. (A) An interaction model between NP and PB2. The NP structure (PDB accession number: 2Q06) was
ﬁtted into the cryo-EM structure of 9-fold symmetric NP (EM DataBank accession number: 1603) with Chimera and Pymol Molecular Graphics System. The cryo-EM structure
of three polymerases (EM DataBank accession number: 2212) was used to simulate the interface of NP with PB2. The amino acid D88 (red) on NP was expectedly located on
the interface of NP with PB2. The region of D88 interaction with PB2 was enlarged on the right. (B) Co-IP result of wild-type and mutant NPs with PB2. Plasmids encoding
wild-type NP or mutant NP fromWSN with PB2 gene of WSN were cotransfected into 293T cells, and cell lysates were prepared 48 h post transfection and precipitated with
anti-NP rabbit polyclonal antibodies and subsequently immunoblotted with anti-PB2 murine antibody. (D) Co-IP result of wild-type and mutant NPs with PB1. Plasmids
encoding wild-type or mutant NP of WSN with PB1 gene of WSN were cotransfected into 293T cells, and cell lysates were prepared 48 h post transfection and precipitated
with anti-NP rabbit polyclonal antibody and subsequently immunoblotted with anti-PB1 murine antibody. (F) Co-IP result of wild-type and mutant NP with PB2 in the
presence of the whole polymerase protein complex. The components of the polymerase protein complex (PB1, PB2, and PA) from WSN with wild-type or mutant NP gene
from WSN were coexpressed in 293T cells, and cell lysates were prepared 48 h post transfection and precipitated with anti-NP rabbit polyclonal antibody and subsequently
immunoblotted with anti-NP, anti-PB1, anti-PB2, and anti-PA murine antibodies by Western blot. (C, E and G) The relative intensities of the bands in Fig. 5B, D, and F were
further quantiﬁed using Quantity One V4.62 software (Bio-Rad). Error bars represent the standard deviation of triplicate assays for each condition. *, Po0.05; **, Po0.01.
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aspartic acid in NP may be a critical site to assemble a high-activity
RNPs by interacting with PB2 and further affect the virus replica-
tion. This result is consistent with the previous report that the
N-terminal of NP is involved in the interaction of NP with PB2
protein (Albo et al., 1995; Biswas et al., 1998; Turan et al., 2004).
The NP protein has been an important antiviral drug target for
inﬂuenza virus due to its high conservation and multiple functions
in virus replication. The NP protein assumes the overall shape of a
crescent consisting of a head domain function as NP–NP homo-
oligomerization and RNA binding, a body domain function as NP–
NP homo-oligomerization, RNA binding and PB2 binding, a deep
groove enriched for basic amino acid residues function as RNA
binding and a tail loop function as NP–NP homo-oligomerization
and PB2 binding (Elton et al., 1999; Ng et al., 2009). Several studies
have reported that a single amino acid substitution in the tail loop
can abolish NP oligomerization and result in inactivity of RNPs,
suggesting the tail loop in NP is a potential antiviral target
(Hagiwara et al., 2010; Ng et al., 2008; Noda et al., 2012; Ye
et al., 2006). Besides the tail loop in NP, several RNA-binding sites
in NP have also been selected as targets in the development of
novel antiviral drugs (Lejal et al., 2013). In this study, D88
recognized by the NP speciﬁc mAb, 19C10, was ﬁrst time identiﬁed
as a highly conserved amino acid with critical function for the
formation of a high-activity RNPs. Compared to the wild-type
WSN virus, the replication of recombinant D88A mutant WSN
virus was reduced signiﬁcantly in vitro and in vivo, suggesting that
this D88 in the body domain of NP plays critical role in virus
replication. Therefore, the D88 region may be a novel potential
target for the development of antiviral drugs against the inﬂuenza
A virus.
In summary, we have identiﬁed a highly conserved aspartic
acid at residue 88 in NP of inﬂuenza A virus by use of a broadly
reactive NP speciﬁc mAb 19C10, molecular docking and site-
speciﬁc mutagenesis methods. This amino acid was veriﬁed as a
key site for virus replication both in vitro and in vivo. Only one
residue was presented here, further structural studies including
crystallography on the complex of NP-19C10 Fv and NP are needed
for characterization of other amino acids in this epitope.
4. Materials and methods
4.1. Cells and viruses
Madin–Darby canine kidney (MDCK) and human embryonic
kidney (293T) cells were maintained in Dulbecco’s modiﬁed
Eagle's medium (Gibco), and SP2/0 was maintained in RPMI-
1640 (Gibco), in all instances supplemented with 10% fetal bovine
serum, 100 IU of penicillin G/ml and 100 ml of streptomycin sulfate/
ml and cultured at 37 1C with 5% CO2. For transfection studies,
subconﬂuent (70%) monolayers were transiently transfected or
cotransfected with plasmids by using TransIT-LT1 transfection
reagent (Mirus). All inﬂuenza virus strains were maintained in
our lab.
4.2. Cloning, expression, and puriﬁcation of the NPs
The plasmid pET22b (Novagen) was selected as the vector for
expressing the NP gene. CDNA copies of the NP gene were
transcribed with RT primer from the genomic RNA of A/WSN/
1933 (WSN), and then ampliﬁed with the cloning primer pair. The
PCR fragments were cloned into pET22b digested with restriction
endonucleases NdeI and SalI. And the site-directed mutagenesis of
the plasmids pET22b containing the wild-type NP genes was used
the site-directed QuickChange Mutagenesis kit (Agilent). Construc-
tions containing wild-type and mutant NP sequences were
expressed in Escherichia coli (E.coli) strain BL21 (DE3). And the
T7 promoter was induced at 25 1C with 1 mM IPTG when the
OD600 of the culture reached 0.7 optical units. Cells were broken
by sonication and then the recombinant NP (rNP) was puriﬁed by
Ni-NTA afﬁnity chromatograph column (Novagen) according to the
manufacturer's protocol.
4.3. Western blot
The reactivity of mAb 19C10 with wild-type and mutant rNPs
was determined by Western blot. The puriﬁed recombinant NPs
were subjected to 12% SDS-PAGE gels and then transferred to
0.22 mm nitrocellulose membranes (GE Healthcare). After blocking,
the membranes were incubated with the mAb 19C10 at 37 1C
for 60 min. After washing three times with PBS containing 0.5%
Tween-20 (PBST), the membranes were inoculated with AP-conju-
gated goat anti-mouse IgG at 37 1C for 60 min and visualized by its
substrates.
4.4. Immunoﬂuorescence assay (IFA)
MDCK cells infected with inﬂuenza virus strains were cultured
for 24 h. The cells were ﬁxed by 4% paraformaldehyde and indirect
immunoﬂuorescence assays were performed. Brieﬂy, cells were
washed twice with PBS, ﬁxed with 4.0% paraformaldehyde (in PBS)
for 20 min at room temperature, washed again, and permeabilized
with 0.5% triton X-100 for 10 min. After being blocked with 10%
BSA for 20 min at room temperature, cells were incubated with an
anti-NP monoclonal antibody (19C10) for 30 min. Cells were then
incubated with ﬂuorescein isothiocyanate labeled goat anti-mouse
antibody immunoglobulin G, 1:200 dilution (Roche) for 30 min,
washed, and examined using a ﬂuorescence microscope.
4.5. Dot-ELISA
In Dot-ELISA, anti-NP mAb was immobilized on a nitrocellulose
membrane, served as the capture antibody, and the anti-NP
polyclonal antibody labeled with horseradish peroxidase was used
as the detecting antibody. The procedure involves mixing 200 ml of
virus with 400 ml of lysis buffer. The mixture was ﬁltered in a
microtiter-like well that had a permeable membrane located at the
bottom of the well with the antigen captured during the ﬁltration
process. The entire test procedure can be completed in 30 min and
the results can be read visually (Chen et al., 2008; Chen et al.,
2010).
4.6. Coimmunoprecipitation Assay (Co-IP)
Four or two plasmids cotransfected 293T cells were lysed and
incubated with anti-NP rabbit polyclonal antibody at 37 1C for
30 min. After the addition of 50 ml of protein A-sepharose beads,
the lysates were incubated at 37 1C for 30 min. The complex bound
to the beads were then eluted into sodium dodecyl sulfate (SDS)
running buffer by heating at 95 1C for 10 min. The samples were
then analyzed by SDS-PAGE and Western blot.
4.7. Analysis of NP gene of inﬂuenza A virus strains
Multiple alignments of amino acid sequences in the nucleo-
protein of different inﬂuenza A virus strains were performed using
Clustal W within the DNASTAR software (version 7.0).
4.8. Luciferase reporter assay for polymerase complex activity
Full-length genomic segments of NP, PA, PB1, and PB2 derived
from WSN, A/PR/8/1934 (PR8) and A/California/04/2009 (CA4)
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were cloned into vector of pHW2000. Mutant NP plasmids were
generated as described above. Components of the RNP complex,
comprising wild-type NP or mutant NP, plus PA, PB1, and PB2,
were cotransfected into 293T cells, together with a luciferase
reporter plasmid, PHY-luci, which contains noncoding sequences
from the M segments of inﬂuenza A virus and the luciferase gene
driven by Poll. At 24 h post transfection, cell lysates were prepared
by using the luciferase assay system (Promega). And luciferase
activity was measured by using a microplate luminometer (Wang
et al., 2009).
4.9. Homology modeling of 19C10 Fv region
The mAb 19C10 Fv region was sequenced ﬁrst. Modeling of the
mAb 19C10 Fv region involved a two-step process. A raw model
was built in the ﬁrst step, using MODELER component in Accelrys
Discovery Studio 2.5. BLAST search was performed against the PDB
database. Light chain and heavy chain were searched indepen-
dently to ﬁnd templates with highest degree in sequence homol-
ogy. The best hit in VL search or VH search was selected as main
template, with both chains retained. For other hits, only relevant
chains were selected for precise modeling. 30 models were built
using the High optimization setting. The top scoring model with
the lowest PDF energy (Probability Density Function energy) was
selected as raw model. The raw model contained the correct target
sequence and correct frame structure, and the six hypervariable
loop regions (L1, L2, L3, H1, H2 and H3, deﬁned by WAM tools;
http://antibody.bath.ac.uk) would be optimized in the second step.
Loop Reﬁnement component was used for optimizing hypervari-
able loops. Generally, if the initial hit found in the ﬁrst step
provided sufﬁcient homology, the loops could be left out in the
second step. In case of poor hits, independent templates search
were done and the loop structure was remodeled and grafted to
the raw model. The ﬁnal model of the mAb 19C10 was energy
minimized with 2000 steps of steepest descent optimization and
5000 steps of conjugated gradient optimization. All the modeled
structures were validated using Proﬁle-3D.
4.10. Molecular docking of mAb 19C10 Fv region with x-ray crystal
structure of NP
Docking of NP and antibody was performed on ZDOCKpro
module of the Insight II package. The general protocol for running
ZDOCK includes two consecutive steps of calculation described as
geometry search and energy search, running in program ZDOCK
and RDOCK, respectively. In order to improve the quality of
docking process, block residues were set to the receptor and
ligand respectively. Inﬂuenza A virus NP crystal structure (2Q06)
was obtained from PDB database. Blocked residues on antibody
(ligand) were deﬁned as predicted frame region, while blocked
residues on NP were deﬁned as residues beyond 5 Å of the loop
regions. Top 50 ZDOCK poses were submitted to RDOCK reﬁne-
ment. Poses with high score both in ZDOCK and RDOCK were
selected as candidate complex for interaction analysis.
4.11. Generation of recombinant virus by reverse genetics
For generation of recombinant inﬂuenza virus, 8 plasmids
encoding the individual viral RNA segments for inﬂuenza A virus
A/WSN/1933 were cotransfected into cocultured MDCK and 293T
cells and the virus was detected by a hemagglutination assay (Jin
et al., 2003). The mutation D88A was introduced into the NP gene
by using a site-directed QuickChange Mutagenesis kit according
the manufacturer's instructions. Viral RNA was extracted and
analyzed by RT-PCR, and the NP gene was sequenced to conﬁrm
the identity of the virus (Zhang et al., 2012).
4.12. Virus titration and replication kinetics
The 50% tissue culture infectious dose (TCID50) was determined
in MDCK cells with 10-fold serially diluted virus inoculated at
37 1C for 72 h. The TCID50 was calculated by the traditional
method. Multistep replication kinetics was determined by inocu-
lating MDCK cells at a multiplicity of infection (MOI) of 0.001
TCID50 per cell. Supernatants were sampled at 12, 24 and 36 h post
inoculation. Virus titers were determined by TCID50 in MDCK cells.
Three independent experiments were performed.
4.13. Replication of inﬂuenza virus in mice
To determine viral replication in mice, nine 6-week-old female
BALB/c mice for each group were anesthetized by isoﬂurane
inhalation and then inoculated intranasally with 25 ml 106 TCID50
of recombinant wild-type and mutant (D88A in NP) WSN virus
diluted in phosphate-buffered saline (PBS). For each group,
three mice were euthanized on 12, 24 and 36 h after inoculation,
respectively. Then the lung tissues were collected and weighed,
and homogenates were prepared in 10 volumes (w/v) of cold PBS.
The homogenates were centrifuged at 3000 rpm for 10 min to
remove cell debris, and then the supernatants were 10-fold serially
diluted for viral titer determination by TCID50 test in MDCK cells.
4.14. RT-PCR assays for vRNA
MDCK cells were infected with 10,000 TCID50 wild-type and
mutant WSN strains, respectively. To study the effect of D88 in NP
on virus genomic RNA in virus replication cycle, total RNA was
extracted at indicated time points post infection by using an RNeasy
kit (Qiagen). Then the speciﬁc primer complementary to the 30 end of
vRNA was used in the reverse transcription (RT) reaction (Hoffmann
et al., 2001). Primers were designed by using the Primer3 website.
WSN-NP-F1 (50- AGTTGGAACAATGGTGATGG-30) and WSN-NP-R1
(50- TTCCGGCTCTCTCTCACTTGATC-30) were used for NP, and WSN-
NS1-F1 (50- CTTCAGTGTGATTTTTGACCG-30) and WSN-NS1-R1
(50- GGAAGAGAGGGCAGTGGTGAA-30) were used for NS1. The ampli-
ﬁcation program was as follows: 95 1C for 10 min, followed by 25
cycles of 95 1C for 40 s, 56 1C for 40 s, and 72 1C for 60 s. Ampliﬁed
products were further analyzed by agarose gel electrophoresis and
sequencing.
4.15. Statistical analysis
Statistical analysis of the differences in the virus titers were
performed by SPSS 11.5 software, and the DUNCAN and LSD
methods were used for detection in one-way ANOVA means. A
probability value o0.05 was considered statistically signiﬁcant.
4.16. Ethics statement
The animal experiments with BALB/c mice were carried out in
strict accordance with recommendations in the Guide for the Care
and Use of Laboratory of Animals of Xiamen University.
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